2025-04-282025-04-282022DORNELES, Gilson P. et al. Alterations in CD39/CD73 axis of T cells associated with COVID-19 severity. Journal of Cellular Physiology, New York, v. 237, n. 8, p. 3394-3407, 2022. DOI: 10.1002/jcp.30805. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/jcp.30805. Acesso em: 17 abr. 2025.0021-9541e- 1097-4652https://onlinelibrary.wiley.com/doi/10.1002/jcp.30805Purinergic signaling modulates immune function and is involved in the immunopathogenesis of several viral infections. This study aimed to investigate alterations in purinergic pathways in coronavirus disease 2019 (COVID-19) patients. Mild and severe COVID-19 patients had lower extracellular adenosine triphosphate and adenosine levels, and higher cytokines than healthy controls. Mild COVID-19 patients presented lower frequencies of CD4+CD25+CD39+ (activated/memory regulatory T cell [mTreg]) and increased frequencies of high-differentiated (CD27−CD28−) CD8+ T cells compared with healthy controls. Severe COVID-19 patients also showed higher frequencies of CD4+CD39+, CD4+CD25−CD39+ (memory T effector cell), and high-differentiated CD8+ T cells (CD27−CD28−), and diminished frequencies of CD4+CD73+, CD4+CD25+CD39+ mTreg cell, CD8+CD73+, and low-differentiated CD8+ T cells (CD27+CD28+) in the blood in relation to mild COVID-19 patients and controls. Moreover, severe COVID-19 patients presented higher expression of PD-1 on low-differentiated CD8+ T cells. Both severe and mild COVID-19 patients presented higher frequencies of CD4+Annexin-V+ and CD8+Annexin-V+ T cells, indicating increased T-cell apoptosis. Plasma samples collected from severe COVID-19 patients were able to decrease the expression of CD73 on CD4+ and CD8+ T cells of a healthy donor. Interestingly, the in vitro incubation of peripheral blood mononuclear cell from severe COVID-19 patients with adenosine reduced the nuclear factor-κB activation in T cells and monocytes. Together, these data add new knowledge to the COVID-19 immunopathology through purinergic regulation.engAcesso RestritoArtigo10.1002/jcp.30805